We are live on
!
Find out more
SI
Sofinnova Investments Portfolio holdings
AUM
$1.93B
1-Year Est. Return
134.74%
This Fund
S&P 500
This Quarter
Est. Return
-7.85%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$394M
(-23%)
Cap. Flow
-$73.4M
Cap. Flow
% of AUM
-5.57%
Top 10 Holdings %
Top 10 Hldgs %
63.8%
Holding
83
New
13
Increased
13
Reduced
16
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$114M |
| 2 |
AstraZeneca
AZN
|
+$33.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$22.5M |
| 4 |
Zoetis
ZTS
|
+$21.1M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$42.2M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$26.3M |
| 3 |
Align Technology
ALGN
|
+$25.1M |
| 4 |
Heron Therapeutics
HRTX
|
+$21.4M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$20.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.14% |
| 2 | Miscellaneous | 9.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $248M | 18.79% |
1,953,077
| – | – |
|
2
Natera
NTRA
$47.4B
| $126M | 9.58% |
3,102,960
| – | – |
|
|
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $97.8M | 7.42% |
+5,573,949
| New | +$114M |
|
4
Vera Therapeutics
VERA
$2.49B
| $74.7M | 5.67% |
3,181,442
+266,666
| +9% | +$5.74M |
|
|
JBIO
5
Jade Biosciences
JBIO
$1.13B
| $68.9M | 5.23% |
107,391
| – | – |
|
6
PUT
Invesco QQQ Trust
QQQ
$488B
| $63.4M | 4.82% |
175,000
+75,000
| +75% | +$26.6M |
|
7
Ascendis Pharma A/S
ASND
$17.4B
| $58.7M | 4.45% |
499,824
| – | – |
|
|
8
AstraZeneca
AZN
$248B
| $36.7M | 2.79% |
+276,952
| New | +$33.2M |
|
9
United Therapeutics
UTHR
$21.4B
| $35.7M | 2.71% |
199,183
+69,429
| +54% | +$13.2M |
|
10
PUT
iShares Russell 2000 ETF
IWM
$78.6B
| $30.8M | 2.34% |
150,000
| – | – |
|
|
YMAB
11
DELISTED
Y-mAbs Therapeutics
YMAB
| $26.1M | 1.98% |
2,194,278
| – | – |
|
|
12
Vertex Pharmaceuticals
VRTX
$131B
| $24.8M | 1.88% |
+95,003
| New | +$22.5M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $24.5M | 1.86% |
232,894
+11,102
| +5% | +$1.08M |
|
14
DexCom
DXCM
$31.4B
| $20.6M | 1.56% |
161,060
+31,444
| +24% | +$3.44M |
|
15
Regenxbio
RGNX
$564M
| $20.4M | 1.55% |
614,085
-393,996
| -39% | -$10.9M |
|
|
16
Zoetis
ZTS
$30B
| $20.1M | 1.53% |
+106,574
| New | +$21.1M |
|
|
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $19.7M | 1.5% |
+602,545
| New | +$17.9M |
|
|
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $18.3M | 1.39% |
572,297
+360,016
| +170% | +$10.3M |
|
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$11B
| $18M | 1.36% |
+200,000
| New | +$18.5M |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.2M | 1.3% |
1,021,211
+222,422
| +28% | +$3.29M |
|
21
Travere Therapeutics
TVTX
$6.29B
| $17M | 1.29% |
658,249
-382,609
| -37% | -$10.2M |
|
22
Guardant Health
GH
$21.3B
| $15.9M | 1.21% |
239,995
+7,432
| +3% | +$509K |
|
|
CCXI
23
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.4M | 1.09% |
573,684
-157,538
| -22% | -$4.43M |
|
24
BioMarin Pharmaceuticals
BMRN
$12.7B
| $13.6M | 1.03% |
176,533
+89,211
| +102% | +$7.46M |
|
25
NextCure
NXTC
$32.5M
| $13M | 0.99% |
222,655
| – | – |
|
Similar funds
GIA
EK
CTI
SI
P3I
TCM
MCWS
SWM
Sofinnova Investments's Q1 2022 Portfolio in Review
As of Q1 2022, Sofinnova Investments held 83 positions worth $1.32B, down 23% from $1.71B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Sofinnova Investments withdrew a net $73.4M in Q1 2022, closing 22 positions and reducing 16 holdings. Its most notable exit was AbbVie, an estimated $42.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Miscellaneous.
Against the trend, Sofinnova Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $97.8M.
- Sofinnova Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 5,573,949 shares worth $97.8M.
- Sofinnova Investments added most to United Therapeutics in Q1 2022, an estimated $13.2M increase.
- Sofinnova Investments's biggest Q1 2022 reduction was Heron Therapeutics, cutting an estimated $21.4M.
- Sofinnova Investments fully exited AbbVie in Q1 2022, selling an estimated $42.2M.
- Sofinnova Investments's ten largest holdings make up 64% of its $1.32B portfolio in Q1 2022.
- Sofinnova Investments opened 13 new positions and closed 22 in Q1 2022.
- Sofinnova Investments's portfolio value fell 23% quarter-over-quarter to $1.32B.
Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.